Skip to search formSkip to main contentSkip to account menu

trebananib

Known as: trenananib 
An angiopoietin (Ang) 1 and 2 neutralizing peptibody, with potential antiangiogenic activity. AMG 386 targets and binds to Ang1 and Ang2, thereby… 
National Institutes of Health

Related topics

Related topics

4 relations

Narrower (1)

AMG 386

Broader (3)

Angiogenesis InhibitorsPharmacologic SubstanceRecombinant Fusion Proteins

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Exceptional Response to Nivolumab Rechallenge in Metastatic Renal Cell Carcinoma with Parallel Changes in Genomic Profile.
2018
2018
Randomized Phase 2 Study of Trebananib (AMG 386) with or without Continued Anti-Vascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma Who Have Progressed on Bevacizumab…
Background: In renal cell carcinoma (RCC), angiopoietin (Ang) 2 is elevated at the time of progression on anti-vascular… 
2016
2016
Angiogenesis inhibitors for patients with ovarian cancer: a meta-analysis of 12 randomized controlled trials
Abstract Objectives: To investigate the effects of angiogenesis inhibitors in the treatment of patients with advanced or… 
Review
2015
Review
2015
Antiangiogenic agents in gynecological cancer: State of art and perspectives of clinical research.
2015
2015
Impact of trebananib plus weekly paclitaxel on overall survival (OS) in patients (pts) with recurrent ovarian cancer and ascites: Results from the phase III TRINOVA-1 study.
5503 Background: Trebananib is an antiangiogenic peptibody that inhibits angiopoietin 1 and 2 binding to the Tie2 receptor… 
Review
2015
Review
2015
Improvements in Progression-Free and Overall Survival Due to the Use of Anti-Angiogenic Agents in Gynecologic Cancers
Opinion statementIn ovarian cancer (OC), the best established anti-angiogenic drug, bevacizumab, has demonstrated only modest… 
2015
2015
Dual targeting of vascular endothelial growth factor-A (VEGF-A) and angiopoietins (Ang) without chemotherapy in metastatic colorectal cancer (mCRC): Results of the VENGEANCE study.
3533 Background: VEGF-A and Ang play complementary roles in regulation of blood vessel growth, maturation and function. Hence we… 
2015
2015
Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors
SummaryBackground Trebananib is an anti-angiogenic peptibody under investigation in patients with advanced cancer. This study… 
2015
2015
Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack
BackgroundThe angiopoietin/Tie2 pathway is an attractive target for cancer therapy due to its well-known role in regulating… 
2014
2014
Phase 1 study of the angiopoietin 1/2 neutralizing peptibody, trebananib, in acute myeloid leukemia.
7082 Background: Angiopoietins (Ang-1/2), pro-angiogenic factors binding to the Tie2 receptor on endothelial cells, have been… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)